Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.77 |
| ▸ | NPC1 | O15118 | 7/20 | 0.77 |
| ▸ | RAB9A | P51151 | 7/20 | 0.77 |
| ▸ | POLB | P06746 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 9/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993239 | 0.85 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL9911664 | 0.81 | MEN1 (0.62) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL29517929 | 0.81 | MEN1 (0.66) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL2985626 | 0.74 | MEN1 (0.76) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL24487208 | 0.73 | MEN1 (0.78) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL20534435 | 0.72 | KDR (0.66) | MEN1KMT2APOLBMAPT | |
| SCHEMBL20534434 | 0.72 | KDR (0.66) | MEN1KMT2APOLBMAPT | |
| SCHEMBL2302380 | 0.71 | KMT2A (0.62) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL2302382 | 0.71 | KMT2A (0.62) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL13057222 | 0.71 | S1PR3 (0.55) | MEN1KMT2ANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022071777-A1 | COMPOSITION AND METHOD FOR PREVENTION OR TREATMENT OF RESPIRATORY DISEASE | 연세대학교 산학협력단 | 2022-04-07 | — | — | WO | claimed |
| WO-2022071777-A1 | COMPOSITION AND METHOD FOR PREVENTION OR TREATMENT OF RESPIRATORY DISEASE | 연세대학교 산학협력단 | 2022-04-07 | — | — | WO | disclosed |
| US-8466177-B2 | Treating and preventing viral infections | THE UAB RESEARCH FOUNDATION (US) | 2013-06-18 | — | — | US | disclosed |
| US-20100286212-A1 | Treating and Preventing Viral Infections | THE UAB RESEARCH FOUNDATION (US) | 2010-11-11 | — | — | US | disclosed |
| US-20070077215-A1 | Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening | L'OREAL (FR) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077215-A1 | Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening | TYR, KRT18, MITF | MEN1 3959/4885KMT2A 82/4885NPC1 3122/4885 |
| US-20100286212-A1 | Treating and Preventing Viral Infections | HAVCR2, IRF3, MAVS | MEN1 3172/4885KMT2A 3809/4885NPC1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.